Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (12 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in clinical relapse (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in maintenance of clinical remission (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events (52 weeks) · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve clinical remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to maintain clinical response · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to maintain clinical response (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve endoscopic remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in adverse events (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).
1 finding from 1 review
Primary outcome: prevention of ulcer · ulceration caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost of the intervention · ulceration caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: quality of life · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: acceptability of treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Costs · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome: prevention of ulcer · ulceration caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ulcer healing · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Primary outcome: adverse events (skin sensitisation at 2 months) · ulceration caused by nerve damage in leprosy
1 finding from 1 review